A majority of the Supreme Court's justices, both conservative and liberal, did not seem inclined to block the FDA's existing rules for prescribing and dispensing the abortion pill mifepristone.
The case is widely seen as a threat not just to the increased accessibility of abortion pills, but to the FDA's entire structure of regulating pharmaceuticals.
